JP2022514569A5 - - Google Patents
Info
- Publication number
- JP2022514569A5 JP2022514569A5 JP2021535041A JP2021535041A JP2022514569A5 JP 2022514569 A5 JP2022514569 A5 JP 2022514569A5 JP 2021535041 A JP2021535041 A JP 2021535041A JP 2021535041 A JP2021535041 A JP 2021535041A JP 2022514569 A5 JP2022514569 A5 JP 2022514569A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- use according
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783947P | 2018-12-21 | 2018-12-21 | |
| US62/783,947 | 2018-12-21 | ||
| PCT/US2019/068094 WO2020132594A1 (en) | 2018-12-21 | 2019-12-20 | Amorphous sparsentan compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514569A JP2022514569A (ja) | 2022-02-14 |
| JP2022514569A5 true JP2022514569A5 (https=) | 2022-11-29 |
Family
ID=69187971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535041A Pending JP2022514569A (ja) | 2018-12-21 | 2019-12-20 | 非晶質スパルセンタン組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220048900A1 (https=) |
| EP (1) | EP3897834A1 (https=) |
| JP (1) | JP2022514569A (https=) |
| KR (1) | KR20210125994A (https=) |
| CN (1) | CN114126712A (https=) |
| AU (1) | AU2019404552A1 (https=) |
| BR (1) | BR112021012226A2 (https=) |
| CA (1) | CA3124127A1 (https=) |
| IL (1) | IL284186A (https=) |
| MA (1) | MA54542A (https=) |
| MX (1) | MX2021007258A (https=) |
| WO (1) | WO2020132594A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53817A (fr) | 2018-10-04 | 2021-08-11 | Travere Therapeutics Inc | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv |
| WO2022266370A1 (en) | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| EP4458826A4 (en) * | 2021-12-28 | 2025-12-24 | Alchemedicine Inc | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| KR20250151548A (ko) * | 2023-02-24 | 2025-10-21 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 방향족 고리계 함유 유도체 길항제의 염, 이의 제조 방법과 응용 |
| CN118666826A (zh) * | 2024-08-23 | 2024-09-20 | 成都臻拓医药科技有限公司 | 一种司帕生坦原料药的重结晶纯化方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| ATE339417T1 (de) * | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
| WO2010114801A1 (en) * | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) * | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| CN117017985A (zh) * | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
-
2019
- 2019-12-20 US US17/415,518 patent/US20220048900A1/en not_active Abandoned
- 2019-12-20 AU AU2019404552A patent/AU2019404552A1/en not_active Abandoned
- 2019-12-20 MX MX2021007258A patent/MX2021007258A/es unknown
- 2019-12-20 MA MA054542A patent/MA54542A/fr unknown
- 2019-12-20 WO PCT/US2019/068094 patent/WO2020132594A1/en not_active Ceased
- 2019-12-20 CA CA3124127A patent/CA3124127A1/en active Pending
- 2019-12-20 JP JP2021535041A patent/JP2022514569A/ja active Pending
- 2019-12-20 CN CN201980092448.1A patent/CN114126712A/zh active Pending
- 2019-12-20 BR BR112021012226-5A patent/BR112021012226A2/pt not_active IP Right Cessation
- 2019-12-20 EP EP19842514.2A patent/EP3897834A1/en not_active Withdrawn
- 2019-12-20 KR KR1020217021973A patent/KR20210125994A/ko not_active Ceased
-
2021
- 2021-06-20 IL IL284186A patent/IL284186A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514569A5 (https=) | ||
| JP2019530713A5 (https=) | ||
| CN1127340C (zh) | 含烟碱复合物的组合物、该组合物的应用及其形成方法 | |
| JP2011511754A5 (https=) | ||
| JP2017523206A5 (https=) | ||
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| JP2012224641A (ja) | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 | |
| JP2019519581A5 (https=) | ||
| JP2013503893A5 (https=) | ||
| JP2015504073A5 (https=) | ||
| CN103945831A (zh) | 医药制剂 | |
| JP2022533968A5 (https=) | ||
| JP2014526508A5 (https=) | ||
| JP2022514569A (ja) | 非晶質スパルセンタン組成物 | |
| US20220339141A1 (en) | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein | |
| JP2021512906A5 (https=) | ||
| JP6316422B2 (ja) | フィンゴリモドの医薬組成物 | |
| CN112449601A (zh) | 含纳呋拉啡口腔崩解片 | |
| JP2021512921A5 (https=) | ||
| JP2025502064A5 (https=) | ||
| JP2022514152A5 (https=) | ||
| ES2674811T3 (es) | Composiciones estables de fesoterodina | |
| CN114585362A (zh) | 治疗制剂及其用途 | |
| JP2021501202A5 (https=) | ||
| RU2021121438A (ru) | Композиции аморфного спарсентана |